Report Detail
Global Recombinant Activated Coagulation Factor VII Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
- RnM4652816 |
- 05 December, 2025 |
- Global |
- 75 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Recombinant Activated Coagulation Factor VII market size was valued at US$ 1308 million in 2024 and is forecast to a readjusted size of USD 1672 million by 2031 with a CAGR of 3.6% during review period.
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for: Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report is a detailed and comprehensive analysis for global Recombinant Activated Coagulation Factor VII market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Activated Coagulation Factor VII market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Activated Coagulation Factor VII market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Activated Coagulation Factor VII market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Activated Coagulation Factor VII market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Activated Coagulation Factor VII
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Activated Coagulation Factor VII market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Recombinant Activated Coagulation Factor VII market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Vial
Prefilled Syringe
Market segment by Application
Hemophilia A
Hemophilia B
Other
Major players covered
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Activated Coagulation Factor VII product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Activated Coagulation Factor VII, with price, sales quantity, revenue, and global market share of Recombinant Activated Coagulation Factor VII from 2020 to 2025.
Chapter 3, the Recombinant Activated Coagulation Factor VII competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Activated Coagulation Factor VII breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Recombinant Activated Coagulation Factor VII market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Activated Coagulation Factor VII.
Chapter 14 and 15, to describe Recombinant Activated Coagulation Factor VII sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Recombinant Activated Coagulation Factor VII Consumption Value by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Vial
- 1.3.3 Prefilled Syringe
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Recombinant Activated Coagulation Factor VII Consumption Value by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Hemophilia A
- 1.4.3 Hemophilia B
- 1.4.4 Other
- 1.5 Global Recombinant Activated Coagulation Factor VII Market Size & Forecast
- 1.5.1 Global Recombinant Activated Coagulation Factor VII Consumption Value (2020 & 2024 & 2031)
- 1.5.2 Global Recombinant Activated Coagulation Factor VII Sales Quantity (2020-2031)
- 1.5.3 Global Recombinant Activated Coagulation Factor VII Average Price (2020-2031)
2 Manufacturers Profiles
- 2.1 Novo Nordisk
- 2.1.1 Novo Nordisk Details
- 2.1.2 Novo Nordisk Major Business
- 2.1.3 Novo Nordisk Recombinant Activated Coagulation Factor VII Product and Services
- 2.1.4 Novo Nordisk Recombinant Activated Coagulation Factor VII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.1.5 Novo Nordisk Recent Developments/Updates
- 2.2 LFB SA HEMA Biologics
- 2.2.1 LFB SA HEMA Biologics Details
- 2.2.2 LFB SA HEMA Biologics Major Business
- 2.2.3 LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Product and Services
- 2.2.4 LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.2.5 LFB SA HEMA Biologics Recent Developments/Updates
- 2.3 AryoGen Pharmed
- 2.3.1 AryoGen Pharmed Details
- 2.3.2 AryoGen Pharmed Major Business
- 2.3.3 AryoGen Pharmed Recombinant Activated Coagulation Factor VII Product and Services
- 2.3.4 AryoGen Pharmed Recombinant Activated Coagulation Factor VII Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.3.5 AryoGen Pharmed Recent Developments/Updates
3 Competitive Environment: Recombinant Activated Coagulation Factor VII by Manufacturer
- 3.1 Global Recombinant Activated Coagulation Factor VII Sales Quantity by Manufacturer (2020-2025)
- 3.2 Global Recombinant Activated Coagulation Factor VII Revenue by Manufacturer (2020-2025)
- 3.3 Global Recombinant Activated Coagulation Factor VII Average Price by Manufacturer (2020-2025)
- 3.4 Market Share Analysis (2024)
- 3.4.1 Producer Shipments of Recombinant Activated Coagulation Factor VII by Manufacturer Revenue ($MM) and Market Share (%): 2024
- 3.4.2 Top 3 Recombinant Activated Coagulation Factor VII Manufacturer Market Share in 2024
- 3.4.3 Top 6 Recombinant Activated Coagulation Factor VII Manufacturer Market Share in 2024
- 3.5 Recombinant Activated Coagulation Factor VII Market: Overall Company Footprint Analysis
- 3.5.1 Recombinant Activated Coagulation Factor VII Market: Region Footprint
- 3.5.2 Recombinant Activated Coagulation Factor VII Market: Company Product Type Footprint
- 3.5.3 Recombinant Activated Coagulation Factor VII Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Recombinant Activated Coagulation Factor VII Market Size by Region
- 4.1.1 Global Recombinant Activated Coagulation Factor VII Sales Quantity by Region (2020-2031)
- 4.1.2 Global Recombinant Activated Coagulation Factor VII Consumption Value by Region (2020-2031)
- 4.1.3 Global Recombinant Activated Coagulation Factor VII Average Price by Region (2020-2031)
- 4.2 North America Recombinant Activated Coagulation Factor VII Consumption Value (2020-2031)
- 4.3 Europe Recombinant Activated Coagulation Factor VII Consumption Value (2020-2031)
- 4.4 Asia-Pacific Recombinant Activated Coagulation Factor VII Consumption Value (2020-2031)
- 4.5 South America Recombinant Activated Coagulation Factor VII Consumption Value (2020-2031)
- 4.6 Middle East & Africa Recombinant Activated Coagulation Factor VII Consumption Value (2020-2031)
5 Market Segment by Type
- 5.1 Global Recombinant Activated Coagulation Factor VII Sales Quantity by Type (2020-2031)
- 5.2 Global Recombinant Activated Coagulation Factor VII Consumption Value by Type (2020-2031)
- 5.3 Global Recombinant Activated Coagulation Factor VII Average Price by Type (2020-2031)
6 Market Segment by Application
- 6.1 Global Recombinant Activated Coagulation Factor VII Sales Quantity by Application (2020-2031)
- 6.2 Global Recombinant Activated Coagulation Factor VII Consumption Value by Application (2020-2031)
- 6.3 Global Recombinant Activated Coagulation Factor VII Average Price by Application (2020-2031)
7 North America
- 7.1 North America Recombinant Activated Coagulation Factor VII Sales Quantity by Type (2020-2031)
- 7.2 North America Recombinant Activated Coagulation Factor VII Sales Quantity by Application (2020-2031)
- 7.3 North America Recombinant Activated Coagulation Factor VII Market Size by Country
- 7.3.1 North America Recombinant Activated Coagulation Factor VII Sales Quantity by Country (2020-2031)
- 7.3.2 North America Recombinant Activated Coagulation Factor VII Consumption Value by Country (2020-2031)
- 7.3.3 United States Market Size and Forecast (2020-2031)
- 7.3.4 Canada Market Size and Forecast (2020-2031)
- 7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe
- 8.1 Europe Recombinant Activated Coagulation Factor VII Sales Quantity by Type (2020-2031)
- 8.2 Europe Recombinant Activated Coagulation Factor VII Sales Quantity by Application (2020-2031)
- 8.3 Europe Recombinant Activated Coagulation Factor VII Market Size by Country
- 8.3.1 Europe Recombinant Activated Coagulation Factor VII Sales Quantity by Country (2020-2031)
- 8.3.2 Europe Recombinant Activated Coagulation Factor VII Consumption Value by Country (2020-2031)
- 8.3.3 Germany Market Size and Forecast (2020-2031)
- 8.3.4 France Market Size and Forecast (2020-2031)
- 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
- 8.3.6 Russia Market Size and Forecast (2020-2031)
- 8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Activated Coagulation Factor VII Sales Quantity by Type (2020-2031)
- 9.2 Asia-Pacific Recombinant Activated Coagulation Factor VII Sales Quantity by Application (2020-2031)
- 9.3 Asia-Pacific Recombinant Activated Coagulation Factor VII Market Size by Region
- 9.3.1 Asia-Pacific Recombinant Activated Coagulation Factor VII Sales Quantity by Region (2020-2031)
- 9.3.2 Asia-Pacific Recombinant Activated Coagulation Factor VII Consumption Value by Region (2020-2031)
- 9.3.3 China Market Size and Forecast (2020-2031)
- 9.3.4 Japan Market Size and Forecast (2020-2031)
- 9.3.5 South Korea Market Size and Forecast (2020-2031)
- 9.3.6 India Market Size and Forecast (2020-2031)
- 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
- 9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America
- 10.1 South America Recombinant Activated Coagulation Factor VII Sales Quantity by Type (2020-2031)
- 10.2 South America Recombinant Activated Coagulation Factor VII Sales Quantity by Application (2020-2031)
- 10.3 South America Recombinant Activated Coagulation Factor VII Market Size by Country
- 10.3.1 South America Recombinant Activated Coagulation Factor VII Sales Quantity by Country (2020-2031)
- 10.3.2 South America Recombinant Activated Coagulation Factor VII Consumption Value by Country (2020-2031)
- 10.3.3 Brazil Market Size and Forecast (2020-2031)
- 10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Quantity by Type (2020-2031)
- 11.2 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Quantity by Application (2020-2031)
- 11.3 Middle East & Africa Recombinant Activated Coagulation Factor VII Market Size by Country
- 11.3.1 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Quantity by Country (2020-2031)
- 11.3.2 Middle East & Africa Recombinant Activated Coagulation Factor VII Consumption Value by Country (2020-2031)
- 11.3.3 Turkey Market Size and Forecast (2020-2031)
- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Market Dynamics
- 12.1 Recombinant Activated Coagulation Factor VII Market Drivers
- 12.2 Recombinant Activated Coagulation Factor VII Market Restraints
- 12.3 Recombinant Activated Coagulation Factor VII Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Recombinant Activated Coagulation Factor VII and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Recombinant Activated Coagulation Factor VII
- 13.3 Recombinant Activated Coagulation Factor VII Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Recombinant Activated Coagulation Factor VII Typical Distributors
- 14.3 Recombinant Activated Coagulation Factor VII Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Recombinant Activated Coagulation Factor VII. Industry analysis & Market Report on Recombinant Activated Coagulation Factor VII is a syndicated market report, published as Global Recombinant Activated Coagulation Factor VII Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of Recombinant Activated Coagulation Factor VII market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
